Frequently Asked Questions
The market is segmented based on , By Type (Electronic Infusion Pumps, Electronic Injection Pens, Electronic Auto-Injectors, Electronic Inhalers, Electronic Capsules, Others), Component (Sensors, Wireless Communicator and Antennas, Micro Pumps and Flow Regulators, Drug Reservoir, Microcontroller, Others), Connectivity (Bluetooth Low Energy (BLE), Wi-Fi, Ethernet, NB-IoT, Others), System Type (Battery-Powered Systems, Rechargeable Systems), Application (Diabetes, Asthma and Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Growth Hormone Therapy, Immunodeficiency Disease, Cardiovascular Disease, Thalassemia, Others), End User (Home Healthcare, Hospitals, Clinics, Ambulatory Centers, Others) – Industry Trends and Forecast to 2030.
.
The Global Electronic Drug Delivery Systems Market size was valued at USD 16139.89 USD Million in 2022.
The Global Electronic Drug Delivery Systems Market is projected to grow at a CAGR of 8.9% during the forecast period of 2023 to 2030.
The major players operating in the market include AstraZeneca, Amgen , Ypsomed AG, Merck KGaA, Bayer AG, Nemera, F. Hoffmann La Roche Ltd, Teva Pharmaceuticals USA , AptarGroup , Novo Nordisk A/S, ViCentra B.V., Medtronic, United Therapeutics Corporation, Companion Medical, Tandem Diabetes Care , Debiotech S.A., Canè S.p.A, Insulet Corporation, BD, B. Braun Melsungen AG.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa.
